Related Experiment Videos
Drug and alternative therapies for hyperlipidemia
1Medical Research Laboratories, Christ Hospital Cardiovascular Research Center, Cincinnati, OH.
Atherosclerosis
|August 1, 1994
Summary
New guidelines and drug discovery are changing hypercholesterolemia (high cholesterol) treatment. Research focuses on novel lipid-lowering agents and optimizing current therapies, including combination treatments.
Area of Science:
- Cardiology
- Pharmacology
- Genetics
Background:
- Recent hypercholesterolemia guidelines emphasize specific therapeutic goals, increasing demand for lipid-lowering agents.
- The past decade has witnessed significant advancements in lipid-lowering drug discovery, with many agents entering clinical trials.
Purpose of the Study:
- To review the current landscape of lipid-lowering agents and their evolving therapeutic applications.
- To highlight recent advances in both pharmacological and non-pharmacological treatments for hypercholesterolemia.
Main Methods:
- Review of current literature on lipid-lowering agents and clinical trial data.
- Analysis of trends in drug discovery, clinical outcomes, and cost-effectiveness studies.
Main Results:
- HMG CoA reductase inhibitors are the most widely used lipid-lowering agents, with several new compounds in development.
- Four main classes of lipid-altering agents are in common use: bile acid binding resins, niacin, fibrates, and HMG CoA reductase inhibitors.
- Significant progress has been made in non-pharmacological treatments, including LDL-receptor gene replacement and selective LDL-apheresis.
Conclusions:
- The field of hypercholesterolemia management is rapidly evolving, driven by new guidelines and therapeutic innovations.
- A combination of optimized pharmacological therapies and advanced non-pharmacological interventions offers improved treatment strategies.